Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
67 participants
INTERVENTIONAL
2012-02-29
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SYR-322 (Alogliptin) QD
SYR-322 25 mg, orally.
Alogliptin
Alogliptin tablets
Insulin
injection
Insulin
Insulin injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alogliptin
Alogliptin tablets
Insulin
Insulin injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The subject signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Exclusion Criteria
2. The subject is considered ineligible for the study for any other reason by the investigator or subinvestigator.
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Takeda
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Senior Manager
Role: STUDY_DIRECTOR
Takeda
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aomori, Aomori, Japan
Hirosaki-shi, Aomori, Japan
Kashiwa-shi, Chiba, Japan
Kisarazu-shi, Chiba, Japan
Kitakyushu-shi, Fukuoka, Japan
Aki-gun, Hiroshima, Japan
Fukuyama-shi, Hiroshima, Japan
Nishinomiya-shi, Hyōgo, Japan
Koga-shi, Ibaraki, Japan
Ushiku-shi, Ibaraki, Japan
Kahoku-gun, Ishikawa-ken, Japan
Hanamaki-shi, Iwate, Japan
Morioka, Iwate, Japan
Kagoshima, Kagoshima-ken, Japan
Satsuma-sendai-shi, Kagoshima-ken, Japan
Kumamoto, Kumamoto, Japan
Minamata-shi, Kumamoto, Japan
Miyazaki, Miyazaki, Japan
Nigata-shi, Niigata, Japan
Hirakata-shi, Osaka, Japan
Osaka, Osaka, Japan
Osaka-sayama-shi, Osaka, Japan
Takatsuki-shi, Osaka, Japan
Yao-shi, Osaka, Japan
Kuki-shi, Saitama, Japan
Ōtsu, Shiga, Japan
Hamamatsu, Shizuoka, Japan
Shizuoka, Shizuoka, Japan
Shimotsuke-shi, Tochigi, Japan
Shinagawa-ku, Tokyo, Japan
Toyama, Toyama, Japan
Sagae-shi, Yamagata, Japan
Yamagata, Yamagata, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kaku K, Mori M, Kanoo T, Katou M, Seino Y. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase. Expert Opin Pharmacother. 2014 Oct;15(15):2121-30. doi: 10.1517/14656566.2014.956722. Epub 2014 Sep 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1127-1525
Identifier Type: REGISTRY
Identifier Source: secondary_id
JapicCTI-121736
Identifier Type: REGISTRY
Identifier Source: secondary_id
SYR-322/CCT-901
Identifier Type: -
Identifier Source: org_study_id